secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001558370-24-002411
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics Q4 revenue up 12% to $20.3M; net loss narrows to $5.4M; first positive cash flow
--------------------------------------------------------------------------------

- Q4 2023 revenue $20.3M (+12% YoY); full-year revenue $71.3M (+9% YoY).
- Q4 net loss $(5.4)M ($(0.19)/share) vs $(8.3)M loss a year ago; first-ever positive cash flow of $1.5M.
- U.S. treatment session revenue up 20% in Q4 to $14.9M; local consumable treatment session revenue up >33%.
- Full-year 2024 revenue guidance $78M-$80M; Q1 2024 guidance $16.7M-$17.7M.
- Launched Better Me Guarantee Provider pilot with ~100 sites; insurers reduce TMS eligibility to 2 medication failures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000155837024002411/0001558370-24-002411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000155837024002411/stim-20240305x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-002411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer